Member access

4-Traders Homepage  >  Shares  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

Delayed Quote. Delayed BATS Europe - 07/24 11:20:57 am
268.6 CHF   +1.13%
1d ago ROCHE : breast cancer drugs keep it on track to meet targets
1d agoDJROCHE : Profit Dented by Currencies
3d agoDJRoche Holding AG 1st Half 2014 -- Forecast
 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
Roche Holding AG is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. As a large biotech company, Roche has truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. It is also a leader in in-vitro... 
Sector
Pharmaceuticals
Calendar
07/24 | 01:00amEarnings Release
Surperformance© rating of Roche Holding Ltd.
Trading Rating : Investor Rating :
More about the company
Financials ( CHF)
Sales 2014 47 370 M
EBIT 2014 17 528 M
Net income 2014 12 206 M
Debt 2014 2 765 M
Yield 2014 3,09%
Sales 2015 49 241 M
EBIT 2015 18 602 M
Net income 2015 13 086 M
Finance 2015 3 002 M
Yield 2015 3,33%
PER 2014 18,54
PER 2015 17,16
EV / Sales 2014 4,89x
EV / Sales 2015 4,59x
Capitalization 228 833 M
More Financials
Latest news on ROCHE HOLDING LTD.
1d ago ROCHE : breast cancer drugs keep it on track to meet targets
1d agoDJROCHE : Profit Dented by Currencies
3d agoDJRoche Holding AG 1st Half 2014 -- Forecast
3d ago ROCHE : FDA Grants Genentech’s Avastin Priority Review for Recurrent Plati..
6d agoDJRoche Not Interested in Large Acquisitions, Says CEO -- Report
6d ago Roche CEO plans to steer clear of big acquisitions
07/15 ROCHE : FDA Grants Genentech’s Avastin Priority Review for Certain Types o..
07/14 ROCHE : Genentech :’s Investigational Medicine Cobimetinib, Used in Combin..
07/02DJEUROPE MARKETS : Alcatel Higher In Europe, But Orange Shares Sour
07/02DJEUROPE MARKETS : Alcatel, Roche Up In Europe, But Orange Shares Sour
07/02 GLAXOSMITHKLINE : Cameron enlists ex-Goldman economist in global superbug fight
07/02 JOHNSON & JOHNSON : Roche to buy U.S. biotech firm Seragon for up to $1.7 billio..
More news
Comments 
Advertisement
Income Statement Evolution
Roche Holding Ltd. : Income Statement Evolution
More Financials
EPS Revisions
Roche Holding Ltd. : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF